Three of the four states had corresponding evidence of human influenza activity from other surveillance systems ...

HealthDay News — After SARS-CoV-2 infection, prevalent metformin use is associated with a slightly lower incidence of death or postacute sequalae of SARS-CoV-2 (PASC), according to a study published ...

HealthDay News — Americans have the worst health care among the world’s wealthy nations, a new report says. People in the US die the earliest and live the sickest lives out of 10 developed countries, ...

FluMist is a nasally-administered influenza vaccine that is indicated for active immunization to prevent influenza disease in individuals 2 to 49 years of age.

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

The Food and Drug Administration (FDA) has approved Miplyffa ™ (arimoclomol) for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) ...

Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk ...

The over-the-counter medical application is intended for individuals aged 18 years and older who have not been previously diagnosed with sleep apnea.

HealthDay News — There are discrepancies between preferred and actual sources of contraceptive information for US adolescents and young adults (AYA), according to a research letter published online ...

Safety profile similar to other trials, with six in 10 sustaining medication overuse headache remission over six months ...

HealthDay News — The demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant depression (TRD) varies from 24 to 62 percent depending on the ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals regarding the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis.